Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes

Martin J. Rutkowski, Manish K. Aghi

Research output: Contribution to journalReview article

Abstract

Introduction: Prolactinomas are unique tumors that may go into both hormonal and radiographic remission with dopamine agonist therapy or transsphenoidal surgery. Regardless of modality, the goals of therapy remain the same: (1) biochemical remission, including reduction of prolactin and normalization of sex hormones; (2) radiographic tumor control, with a range including prevention of tumor growth, tumor regression, or complete tumor resolution; (3) resolution of preoperative symptoms, including those that are hormonal or neurologic; and (4) prevention of new hypopituitarism or new neurologic symptoms. Areas covered: In the following review, we performed a search of the literature using keywords ‘prolactinoma,’ ‘dopamine agonist,’ ‘surgery,’ ‘cost-effectiveness,’ ‘recurrence,’ and ‘complication’ to compare the relative merits of medical versus surgical therapy for prolactinoma, including special circumstances such as cystic tumors, pregnant patients, and the cost-effectiveness of different strategies. Expert commentary: Medical therapy can offer a cure, but surgery provides an important adjunct to patients with resistance or intolerance to dopamine agonists, and offers excellent outcomes including when combined with continued postoperative medical therapy. Further head to head comparisons will benefit patients and practitioners weighing the relative risks and benefits of medical and surgical intervention, including the issue of their relative cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalExpert Review of Endocrinology and Metabolism
Volume13
Issue number1
DOIs
StatePublished - Jan 2 2018
Externally publishedYes

Fingerprint

Prolactinoma
Dopamine Agonists
Cost-Benefit Analysis
Neoplasms
Therapeutics
Hypopituitarism
Gonadal Steroid Hormones
Neurologic Manifestations
Prolactin
Nervous System
Recurrence
Growth

Keywords

  • adenoma
  • dopamine agonist
  • pituitary
  • Prolactinoma
  • surgery

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Medical versus surgical treatment of prolactinomas : an analysis of treatment outcomes. / Rutkowski, Martin J.; Aghi, Manish K.

In: Expert Review of Endocrinology and Metabolism, Vol. 13, No. 1, 02.01.2018, p. 25-33.

Research output: Contribution to journalReview article

@article{f455d7ec553e4cec8bb9b4aca30f79f5,
title = "Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes",
abstract = "Introduction: Prolactinomas are unique tumors that may go into both hormonal and radiographic remission with dopamine agonist therapy or transsphenoidal surgery. Regardless of modality, the goals of therapy remain the same: (1) biochemical remission, including reduction of prolactin and normalization of sex hormones; (2) radiographic tumor control, with a range including prevention of tumor growth, tumor regression, or complete tumor resolution; (3) resolution of preoperative symptoms, including those that are hormonal or neurologic; and (4) prevention of new hypopituitarism or new neurologic symptoms. Areas covered: In the following review, we performed a search of the literature using keywords ‘prolactinoma,’ ‘dopamine agonist,’ ‘surgery,’ ‘cost-effectiveness,’ ‘recurrence,’ and ‘complication’ to compare the relative merits of medical versus surgical therapy for prolactinoma, including special circumstances such as cystic tumors, pregnant patients, and the cost-effectiveness of different strategies. Expert commentary: Medical therapy can offer a cure, but surgery provides an important adjunct to patients with resistance or intolerance to dopamine agonists, and offers excellent outcomes including when combined with continued postoperative medical therapy. Further head to head comparisons will benefit patients and practitioners weighing the relative risks and benefits of medical and surgical intervention, including the issue of their relative cost-effectiveness.",
keywords = "adenoma, dopamine agonist, pituitary, Prolactinoma, surgery",
author = "Rutkowski, {Martin J.} and Aghi, {Manish K.}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/17446651.2018.1411798",
language = "English (US)",
volume = "13",
pages = "25--33",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Medical versus surgical treatment of prolactinomas

T2 - an analysis of treatment outcomes

AU - Rutkowski, Martin J.

AU - Aghi, Manish K.

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Prolactinomas are unique tumors that may go into both hormonal and radiographic remission with dopamine agonist therapy or transsphenoidal surgery. Regardless of modality, the goals of therapy remain the same: (1) biochemical remission, including reduction of prolactin and normalization of sex hormones; (2) radiographic tumor control, with a range including prevention of tumor growth, tumor regression, or complete tumor resolution; (3) resolution of preoperative symptoms, including those that are hormonal or neurologic; and (4) prevention of new hypopituitarism or new neurologic symptoms. Areas covered: In the following review, we performed a search of the literature using keywords ‘prolactinoma,’ ‘dopamine agonist,’ ‘surgery,’ ‘cost-effectiveness,’ ‘recurrence,’ and ‘complication’ to compare the relative merits of medical versus surgical therapy for prolactinoma, including special circumstances such as cystic tumors, pregnant patients, and the cost-effectiveness of different strategies. Expert commentary: Medical therapy can offer a cure, but surgery provides an important adjunct to patients with resistance or intolerance to dopamine agonists, and offers excellent outcomes including when combined with continued postoperative medical therapy. Further head to head comparisons will benefit patients and practitioners weighing the relative risks and benefits of medical and surgical intervention, including the issue of their relative cost-effectiveness.

AB - Introduction: Prolactinomas are unique tumors that may go into both hormonal and radiographic remission with dopamine agonist therapy or transsphenoidal surgery. Regardless of modality, the goals of therapy remain the same: (1) biochemical remission, including reduction of prolactin and normalization of sex hormones; (2) radiographic tumor control, with a range including prevention of tumor growth, tumor regression, or complete tumor resolution; (3) resolution of preoperative symptoms, including those that are hormonal or neurologic; and (4) prevention of new hypopituitarism or new neurologic symptoms. Areas covered: In the following review, we performed a search of the literature using keywords ‘prolactinoma,’ ‘dopamine agonist,’ ‘surgery,’ ‘cost-effectiveness,’ ‘recurrence,’ and ‘complication’ to compare the relative merits of medical versus surgical therapy for prolactinoma, including special circumstances such as cystic tumors, pregnant patients, and the cost-effectiveness of different strategies. Expert commentary: Medical therapy can offer a cure, but surgery provides an important adjunct to patients with resistance or intolerance to dopamine agonists, and offers excellent outcomes including when combined with continued postoperative medical therapy. Further head to head comparisons will benefit patients and practitioners weighing the relative risks and benefits of medical and surgical intervention, including the issue of their relative cost-effectiveness.

KW - adenoma

KW - dopamine agonist

KW - pituitary

KW - Prolactinoma

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85039165181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039165181&partnerID=8YFLogxK

U2 - 10.1080/17446651.2018.1411798

DO - 10.1080/17446651.2018.1411798

M3 - Review article

C2 - 30063440

AN - SCOPUS:85039165181

VL - 13

SP - 25

EP - 33

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 1

ER -